The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity in patients with relapsed/refractory multiple myeloma.
The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity at doses up to 1,200 mg per day in patients with relapsed/refractory multiple myeloma, according to the results of a phase I study. Responses occurred predominantly in patients with t(11;14) abnormality and those with a favorable genetic profile. The results of the study were published in Blood.
“The oral BCL-2 inhibitor venetoclax at a daily dose up to 1,200 mg demonstrated single-agent anti-myeloma activity in patients with relapsed/refractory multiple myeloma positive for t(11;14), for whom multiple prior lines of therapy have failed,” wrote Shaji Kumar, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues. “Venetoclax has a unique mechanism of action and may offer a novel biologic-driven approach in multiple myeloma.”
Patients with relapsed/refractory multiple myeloma received venetoclax monotherapy at either 300-, 600-, 900-, or 1,200-mg doses. All patients had a 2-week lead-in with weekly dose escalation. Thirty patients participated in the dose-escalation cohorts, and 36 participated in the 1,200-mg safety expansion cohort. The median age of patients was 63 years.
Patients in the study had received a median of five prior therapies. The majority (61%) were bortezomib and lenalidomide double refractory, and about one-half (46%) had t(11;14) abnormality.
Treatment with venetoclax resulted in an overall response rate of 21%, with 15% of patients achieving a very good partial response or better. Most of the responses that occurred were in patients with t(11;14); the overall response rate was 40%, with 27% of patients achieving a very good partial response or better.
The median duration of response was 9.7 months, with a median time to progression of 2.6 months. Patients with t(11;14) also had a median duration of response of 9.7 months, but they had a median time to progression of 6.6 months compared with 1.9 months in patients without t(11;14).
The responses seen in patients with t(11;14) did not seem to be affected by the prior number of therapies or refractoriness to prior therapies. The overall response rate was 22% in patients with one to three prior therapies compared with 48% in patients who had four or more.
Finally, the researchers conducted a biomarker analysis that showed that response to venetoclax was correlated with higher BCL2:BCL2L1 and BCL2:MCL1 mRNA expression ratios.
Overall, treatment with venetoclax was well tolerated. The most commonly occurring adverse events were mild gastrointestinal symptoms, such as nausea (47%), diarrhea (36%), and vomiting (21%). Of the grade 3/4 events, cytopenias were the most common, with thrombocytopenia (32%), neutropenia (27%), anemia (23%), and leukopenia (23%) reported.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.